Bexarotene, a drug used for treating cutaneous T-cell lymphoma, targets the RARG gene, with variations in this gene affecting the drugâ€™s effectiveness and side effects. These genetic differences influence how bexarotene interacts with RARG, altering pharmacodynamics and impacting treatment outcomes by modifying receptor engagement and activation in cells, particularly in skin and lung tissues.